These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
776 related articles for article (PubMed ID: 17921185)
1. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185 [TBL] [Abstract][Full Text] [Related]
2. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265 [TBL] [Abstract][Full Text] [Related]
3. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882 [TBL] [Abstract][Full Text] [Related]
4. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912 [TBL] [Abstract][Full Text] [Related]
5. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Wells G; Li T; Tugwell P Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444 [TBL] [Abstract][Full Text] [Related]
6. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865 [TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH; Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582 [TBL] [Abstract][Full Text] [Related]
8. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Mease P; Genovese MC; Gladstein G; Kivitz AJ; Ritchlin C; Tak PP; Wollenhaupt J; Bahary O; Becker JC; Kelly S; Sigal L; Teng J; Gladman D Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258 [TBL] [Abstract][Full Text] [Related]
10. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357 [TBL] [Abstract][Full Text] [Related]
11. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC; Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627 [TBL] [Abstract][Full Text] [Related]
12. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Schiff M; Pritchard C; Huffstutter JE; Rodriguez-Valverde V; Durez P; Zhou X; Li T; Bahrt K; Kelly S; Le Bars M; Genovese MC Ann Rheum Dis; 2009 Nov; 68(11):1708-14. PubMed ID: 19074911 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Kremer JM; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Westhovens R; Li T; Zhou X; Becker JC; Aranda R; Peterfy C; Genant HK Ann Rheum Dis; 2011 Oct; 70(10):1826-30. PubMed ID: 21893583 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial. Ogrendik M Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134 [TBL] [Abstract][Full Text] [Related]
15. Role of abatacept in the management of rheumatoid arthritis. Nogid A; Pham DQ Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998 [TBL] [Abstract][Full Text] [Related]
16. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. Weinblatt ME; Moreland LW; Westhovens R; Cohen RB; Kelly SM; Khan N; Pappu R; Delaet I; Luo A; Gujrathi S; Hochberg MC J Rheumatol; 2013 Jun; 40(6):787-97. PubMed ID: 23588946 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472 [TBL] [Abstract][Full Text] [Related]
19. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491 [TBL] [Abstract][Full Text] [Related]
20. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]